• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by AcelRx Pharmaceuticals Inc.

    11/22/23 4:34:42 PM ET
    $ACRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACRX alert in real time by email
    S-8 1 acrx20231106_s8.htm FORM S-8 acrx20231106_s8.htm

     

    As filed with the Securities and Exchange Commission on November 22, 2023         

    Registration No. 333-



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     


     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     


     

    ACELRX PHARMACEUTICALS, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware

     

    41-2193603

    (State or other jurisdiction of Incorporation or organization)

     

    (I.R.S. Employer Identification No.)

     


     

    1850 Gateway Drive, Suite 175

    San Mateo, CA 94404

    (Address of principal executive offices) (Zip code)

     


     

    Amended and Restated 2020 Equity Incentive Plan

    (Full title of the plan)

     


     

    Raffi Asadorian

    Chief Financial Officer

    AcelRx Pharmaceuticals, Inc.

    1850 Gateway Drive, Suite 175

    San Mateo, CA 94404

    (650) 216-3500

    (Name and address of agent for service) (Telephone number, including area code, of agent for service)

     


     

    Copy to:

    John T. McKenna

    Cooley LLP

    3175 Hanover Street

    Palo Alto, California 94304

    (650) 843-5000

     


     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer ☐

    Accelerated filer ☐

    Non-accelerated filer ☒ 

    Smaller reporting company ☒

    Emerging growth company ☐

     

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 is being filed for the purpose of registering 1,500,000 additional shares of the common stock of AcelRx Pharmaceuticals, Inc. (the “Registrant”) to be issued pursuant to the Registrant’s Amended and Restated 2020 Equity Incentive Plan (the “2020 Equity Incentive Plan”). The contents of the Registrant’s registration statements on Form S-8 (SEC File Nos. 333-239213 and 333-258896) filed with the Securities and Exchange Commission (the “Commission”) on June 16, 2020 and August 18, 2021, respectively, are incorporated by reference pursuant to General Instruction E of Form S-8.

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    As permitted by the rules of the Commission, this Registration Statement omits the information specified in Part I of Form S-8. The documents containing the information specified in Part I will be delivered to the participants in the 2020 Equity Incentive Plan, as applicable, as required by Rule 428(b)(1) under the Securities Act of 1933, as amended.

     

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3.         Incorporation of Documents by Reference.

     

    The following documents have been filed by the Registrant with the Commission and are incorporated herein by reference:

     

     

    ●

    The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Commission on March 31, 2023; as amended by the Registrant’s Annual Report on Form 10-K/A for the year ended December 31, 2022, filed with the Commission on May 1, 2023;

     

     

    ●

    The Registrant’s Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2023, June 30, 2023, and September 30, 2023, filed with the Commission on May 10, 2023, August 10, 2023, and November 14, 2023, respectively;

     

     

    ●

    The Registrant’s Current Reports on Form 8-K filed with the Commission on March 16, 2023, March 30, 2023 (other than Item 2.02), April 7, 2023 (other than Item 7.01), April 28, 2023, June 15, 2023, July 21, 2023, August 1, 2023, September 22, 2023, October 5, 2023, October 10, 2023, and October 20, 2023; and

     

     

    ●

    the description of our common stock in our registration statement on Form 8-A filed with the Commission on February 1, 2011, as updated by Exhibit 4.1 to our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Commission on March 15, 2021, and any amendments or reports filed for the purpose of updating such description.

     

    All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended, other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items, prior to the filing of a post-effective amendment to this Registration Statement which indicates that all of the shares of Common Stock offered have been sold or which deregisters all of such shares then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing of such documents.

     

    For purposes of this Registration Statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

     

     

     

    Item 8. Exhibits.

     

           

    Incorporation by Reference

    Exhibit Number

     

    Exhibit Description

     

    Form

     

    SEC File No.

     

    Exhibit

     

    Filing Date

    3.1

     

    Amended and Restated Certificate of Incorporation of the Registrant.

     

    8-K

     

    001-35068

     

    3.1

     

    2/18/2011

    3.2

     

    Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Registrant.

     

    8-K

     

    001-35068

     

    3.1

     

    6/25/2019

    3.3

     

    Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Registrant.

     

    8-K

     

    001-35068

     

    3.1

     

    10/25/2022

    3.5

     

    Amended and Restated Bylaws of the Registrant.

     

    8-K

     

    001-35068

     

    3.1

     

    8/12/2022

    4.1

     

    Reference is made to Exhibits 3.1 through 3.4.

                   

    4.2

     

    Specimen Common Stock Certificate of the Registrant.

     

    S-1/A

     

    333-170594

     

    4.2

     

    1/31/2011

    5.1

     

    Opinion of Cooley LLP.

                   

    23.1

     

    Consent of WithumSmith+Brown, PC, Independent Registered Public Accounting Firm.

                   

    23.2

     

    Consent of Cooley LLP (included in Exhibit 5.1).

                   

    24.1

     

    Power of Attorney. Reference is made to the signature page of this Form S-8.

                   

    99.1+

     

    Amended and Restated 2020 Equity Incentive Plan.

     

    8-K

     

    001-35068

     

    10.1

     

    10/10/2023

    107

     

    Filing Fee Table

                   

     


    +          Indicates management contract or compensatory plan.

     

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S‑8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Mateo, State of California, on November 22, 2023.

     

    ACELRX PHARMACEUTICALS, INC.

     
           
     

    By:

    /s/ Vincent J. Angotti 

     
       

    Vincent J. Angotti

     
       

    Chief Executive Officer

     

     

    POWER OF ATTORNEY

     

    Know all persons by these presents, that each person whose signature appears below constitutes and appoints VINCENT J. ANGOTTI and RAFFI ASADORIAN, and each or any one of them, his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

    Title

    Date

         

    /s/ Vincent J. Angotti

    Chief Executive Officer and Director

    November 22, 2023

    Vincent J. Angotti

    (Principal Executive Officer)

     
         

    /s/ Raffi Asadorian

    Chief Financial Officer

    November 22, 2023

    Raffi Asadorian

    (Principal Financial and Accounting Officer)

     
         

    /s/ Adrian Adams

    Chairman

    November 22, 2023

    Adrian Adams

       
         

    /s/ Richard Afable

    Director

    November 22, 2023

    Richard Afable

       
         

    /s/ Marina Bozilenko

    Director

    November 22, 2023

    Marina Bozilenko

       
         

    /s/ Jill Broadfoot

    Director

    November 22, 2023

    Jill Broadfoot

       
         

    /s/ Stephen J. Hoffman

    Director

    November 22, 2023

    Stephen J. Hoffman

       
         

    /s/ Pamela P. Palmer

    Director

    November 22, 2023

    Pamela P. Palmer

       
         

    /s/ Howard B. Rosen

    Director

    November 22, 2023

    Howard B. Rosen

       
         

    /s/ Mark Wan

    Director

    November 22, 2023

    Mark Wan

       

     

     
    Get the next $ACRX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ACRX

    DatePrice TargetRatingAnalyst
    8/17/2021$7.00 → $5.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ACRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on AcelRx Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of AcelRx Pharmaceuticals with a rating of Buy and set a new price target of $5.00 from $7.00 previously

      8/17/21 6:22:04 AM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Dasu Badri N covered exercise/tax liability with 1,618 shares, decreasing direct ownership by 9% to 17,153 units (SEC Form 4)

      4 - TALPHERA, INC. (0001427925) (Issuer)

      2/13/24 9:46:15 PM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Palmer Pamela P covered exercise/tax liability with 1,602 shares, decreasing direct ownership by 4% to 35,344 units (SEC Form 4)

      4 - TALPHERA, INC. (0001427925) (Issuer)

      2/13/24 9:44:54 PM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Asadorian Raffi covered exercise/tax liability with 1,790 shares, decreasing direct ownership by 8% to 20,291 units (SEC Form 4)

      4 - TALPHERA, INC. (0001427925) (Issuer)

      2/13/24 9:42:43 PM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRX
    Leadership Updates

    Live Leadership Updates

    See more
    • AcelRx Pharmaceuticals Announces the Appointment of Jill Broadfoot to its Board of Directors

      HAYWARD, Calif., Nov. 23, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the appointment of Jill Broadfoot to the company's Board of Directors. Ms. Broadfoot currently serves as the Chief Financial Officer (CFO) of aTyr Pharma, Inc., a position she has held since July 2018. Prior to joining aTyr, Ms. Broadfoot served as CFO of Emerald Health Pharmaceuticals and Emerald Health Bioceuticals, where she was responsible for establishing operations for the U.S.-based pharmaceutical and bioceutical entities as well as

      11/23/21 5:09:00 PM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adamis Announces Appointment of Meera Desai, Ph.D., to Board of Directors

      SAN DIEGO, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced the appointment of Meera J. Desai, Ph.D., as a new director and member of the company's board of directors. Dr. Desai replaces Roshawn Blunt, who retired from the Board effective October 1, 2021. Richard Williams, Chairman of the Board, commented: "We are pleased to welcome Dr. Desai to the Board and look forward to working with her to pursue long-term value creation. Her substantial expertise in international pharmaceutical licensing, combined with her background in drug development and commercialization will help us refine corporate strategy to maximize our product pipeline. I

      10/4/21 7:30:00 AM ET
      $ACRX
      $ADMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AcelRx Pharmaceuticals Announces Appointment of Marina Bozilenko to the Board of Directors

      REDWOOD CITY, Calif., March 31, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the appointment of Marina Bozilenko as an independent member of the company's Board of Directors. Ms. Bozilenko has over 30 years of investment banking and other healthcare industry experience, including raising more than $30 billion in capital and executing numerous M&A transactions. She currently serves as a strategic advisor to William Blair & Company, a firm she joined in 2010 as head of biotech & pharma and managing director.

      3/31/21 8:30:00 AM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRX
    Financials

    Live finance-specific insights

    See more
    • AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update

      Capital raise closed in July, led by new healthcare investors; provides access to up to $26.3 million in capital, with $10 million immediately available AcelRx awaits response to Emergency Use Authorization (EUA) of Niyad™ submitted to the FDA in April; registrational study set to initiate in Q4 2023 Proforma $17.4 million in cash as of June 30, 2023, including gross proceeds from financing closed in July 2023 Senior debt with Oxford fully repaid in Q2 2023 Webcast and conference call to be held today at 4:30 p.m. EDT SAN MATEO, Calif., Aug. 10, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commer

      8/10/23 4:05:00 PM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AcelRx to Host Second Quarter 2023 Financial Results Call and Webcast on August 10, 2023

      HAYWARD, Calif., July 27, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release second quarter 2023 financial results after market close on Thursday, August 10, 2023, then host a live webcast and conference call at 4:30 p.m. Eastern Daylight Time/1:30 p.m. Pacific Daylight Time to discuss the results and provide an update on the Company's business.   Webcast Information The webcast can be accessed here or by visiting the Investors section of the Company's website at www.acelrx.com and cl

      7/27/23 4:05:00 PM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

      Request for Emergency Use Authorization of Niyad™ submitted to the FDA in April Divestment of DSUVIA® to Alora Pharmaceuticals closed April 3, 2023 $13.4 million in cash as of March 31, 2023 Webcast and conference call to be held today at 4:30 p.m. EDT HAYWARD, Calif., May 10, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its first quarter 2023 financial results and provided a corporate update. "We have embarked on a new AcelRx chapter by closing the DSUVIA transaction and submitting the request for a

      5/10/23 4:05:00 PM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRX
    SEC Filings

    See more
    • SEC Form EFFECT filed by AcelRx Pharmaceuticals Inc.

      EFFECT - TALPHERA, INC. (0001427925) (Filer)

      2/14/24 12:15:23 AM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B7 filed by AcelRx Pharmaceuticals Inc.

      424B7 - TALPHERA, INC. (0001427925) (Filer)

      2/13/24 4:27:26 PM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-3 filed by AcelRx Pharmaceuticals Inc.

      S-3 - TALPHERA, INC. (0001427925) (Filer)

      2/6/24 4:44:41 PM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Angotti Vincent J. bought $7,268 worth of shares (10,000 units at $0.73), increasing direct ownership by 11% to 101,805 units (SEC Form 4)

      4 - ACELRX PHARMACEUTICALS INC (0001427925) (Issuer)

      12/14/23 8:11:04 AM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AcelRx Announces Rebranding With Name Change to Talphera, Inc.

      Name change to "Talphera" reflects a new era of the Company in partnership with the medical community developing novel solutions for medically supervised settings Talphera will begin trading on Nasdaq under the trading symbol "TLPH" effective January 10 SAN MATEO, Calif., Jan. 9, 2024 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the rebranding of the Company, with a name change to Talphera, Inc. ("Talphera"). The rebrand decision was made to reflect the Company's strategy of developing and commercializin

      1/9/24 9:05:00 AM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States

      Use of CRRT increased during COVID and remained at these higher utilization levels Study results demonstrate challenges physicians have with heparin and citrate, the two currently available CRRT anticoagulants  SAN MATEO, Calif., Dec. 12, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the publication of a quantitative market research study evaluating current U.S. physician anticoagulation use during continuous renal replacement therapy (CRRT) in patients with acute kidney injury in the intensive care unit.  Th

      12/12/23 8:30:00 AM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study

       Investigational Device Exemption (IDE) approval by the U.S. Food and Drug Administration (FDA) allows AcelRx to begin pivotal study of Niyad™ Single registration study with pre-agreed upon endpoints planned to initiate in Q4 2023 with topline data expected mid-2024; clinical site readiness is currently underway Niyad would be the first and only approved regional anticoagulant in the U.S. for the extracorporeal circuit, if approved by the FDA SAN MATEO, Calif., Oct. 3, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, t

      10/3/23 8:30:00 AM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by AcelRx Pharmaceuticals Inc. (Amendment)

      SC 13G/A - TALPHERA, INC. (0001427925) (Subject)

      2/14/24 2:58:44 PM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by AcelRx Pharmaceuticals Inc. (Amendment)

      SC 13G/A - TALPHERA, INC. (0001427925) (Subject)

      2/13/24 8:00:48 PM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by AcelRx Pharmaceuticals Inc.

      SC 13D - TALPHERA, INC. (0001427925) (Subject)

      1/22/24 6:46:08 PM ET
      $ACRX
      Biotechnology: Pharmaceutical Preparations
      Health Care